Catabasis Pharma Cmn (CATB) 4.14 $CATB Mallinck
Post# of 273254
Posted On: 09/21/2016 9:21:01 AM
Catabasis Pharma Cmn (CATB) 4.14 $CATB
Mallinckrodt DMD Drug Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:57AM CDT
Mallinckrodt (MNK) received Fast Track status in the U.S. for its IND application for Synacthen Depot for the treatment of Duchenne muscular dystrophy.
MNK: 74.10 (-1.31), CATB: 4.14 (+0.18), ANIP: 64.84 (+1.09), SRPT: 58.10 (+2.37)
Catabasis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights
BusinessWire - Thu Aug 11, 3:10PM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016 and corporate highlights.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals to Present at 2016 Wedbush PacGrow Healthcare Conference
BusinessWire - Tue Aug 09, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate and pipeline overview at the upcoming 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 1:20pm ET at the Le Parker Meridien Hotel in New York, NY.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals to Report Second Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, August 11
BusinessWire - Thu Jul 28, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2016 financial results after the NASDAQ Global Market close on Thursday, August 11, 2016. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 4:30pm ET to provide an update on corporate developments and to discuss second quarter financial results.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals to Present Edasalonexent (CAT-1004), an Oral Agent Targeting NF-kB: MoveDMD(SM) Trial in Duchenne Muscular Dystrophy (DMD) at the 2016 PPMD Annual Connect Conference
BusinessWire - Mon Jun 20, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that edasalonexent (CAT-1004) will be featured in an oral presentation and a poster presentation at the upcoming 2016 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference being held on Sunday, June 26 - Wednesday, June 29, 2016 at the Renaissance Orlando at Sea World Hotel in Orlando, FL.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on MoveDMD(SM): A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy
BusinessWire - Wed Jun 08, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Parent Project Muscular Dystrophy (PPMD) will host a webinar "MoveDMD: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy" this afternoon on Wednesday, June 8, 2016 at 1:00 pm ET.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Announces Top-Line Phase 2a Results for CAT-2054
BusinessWire - Tue Jun 07, 3:15PM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced top-line results from its Phase 2a clinical trial of CAT-2054 for the treatment of hypercholesterolemia. CAT-2054 is an oral product candidate that inhibits Sterol Regulatory Element-Binding Protein (SREBP), a master regulator of lipid metabolism in the body. The double-blind, placebo-controlled trial assessed the effects of four weeks of treatment with CAT-2054 in patients with hypercholesterolemia on a high-intensity statin. The trial did not meet the primary end point in hypercholesterolemia, reduction in LDL-cholesterol (LDL-C) from baseline. Additional pre-specified analyses included changes in liver function tests (LFTs) to assess potential activity in nonalcoholic steatohepatitis (NASH). In a pre-specified analysis of patients more likely to have NASH, a potentially favorable pattern in LFTs was seen despite relatively low baseline LFT values and short trial duration and needs further investigation. All four doses of CAT-2054 in the trial were generally well tolerated.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016; Data Support CAT-2054, a Phase 2 Asset, as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH)
BusinessWire - Sat May 21, 11:30AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced positive pre-clinical data supporting CAT-2054 as a potential treatment for nonalcoholic steatohepatitis (NASH). The data presented compared CAT-2003, an analog of CAT-2054, versus control in a murine metabolic model of NASH followed for up to 16 weeks. The CAT-2000 series are inhibitors of Sterol Regulatory Element-Binding Protein 1 (SREBP1) and SREBP2, master regulators of lipid metabolism. CAT-2003 demonstrated a significant decrease in gene expression markers of liver inflammation as well as a significant decrease in fibrosis and steatosis. Also seen were significantly reduced ballooning degeneration and significant reduction in the development of pre-neoplastic lesions in the liver, which are precursors to the development of hepatocellular carcinoma. CAT-2054 is an oral product candidate currently in a Phase 2a clinical trial in patients with hypercholesterolemia, which has completed enrollment; top-line results are expected around mid-year 2016.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals to Present Pre-Clinical Data Supporting CAT-2054 as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) at Digestive Disease Week 2016
BusinessWire - Mon May 16, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that pre-clinical data will be presented that supports CAT-2054 as a potential treatment for NASH at Digestive Disease Week 2016 held May 21 - 24, 2016, in San Diego, California at the San Diego Convention Center. The data that will be presented was generated using CAT-2003, an analog of CAT-2054, to demonstrate the potential of CAT-2054 in NASH. CAT-2054 is currently in a Phase 2a clinical trial in patients with hypercholesterolemia.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals to Present CAT-2054, a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) and Hypercholesterolemia, at the National Lipid Association 2016 Scientific Sessions
BusinessWire - Mon May 16, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present CAT-2054, a potential treatment for NASH and hypercholesterolemia, at the upcoming National Lipid Association 2016 Scientific Sessions held May 19 - 22, 2016, in New Orleans at the New Orleans Hyatt Regency Hotel.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Corporate Highlights
BusinessWire - Thu May 12, 3:05PM CDT
-- CAT-2054 as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) and Hypercholesterolemia: Promising Pre-Clinical Data in NASH; Phase 2a Trial in Hypercholesterolemia Fully Enrolled --
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals to Report First Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, May 12
BusinessWire - Thu Apr 28, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2016 financial results after the NASDAQ Global Market close on Thursday, May 12, 2016. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 4:30pm ET to provide an update on corporate developments and to discuss first quarter financial results.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Initiates Part B of the MoveDMD(SM) Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy
BusinessWire - Tue Apr 12, 7:00AM CDT
"Catabasis announced that dosing of the first patient has been initiated in Part B of the MoveDMD trial. They also announced positive biomarker results from Part A of the trial."
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the XIV International Conference on Duchenne and Becker Muscular Dystrophy
BusinessWire - Wed Feb 10, 7:00AM CST
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company focused on bringing transformative therapies to patients with rare diseases, today announced that Catabasis will present CAT-1004 for the treatment of Duchenne muscular dystrophy (DMD) and the MoveDMD(SM) trial design at the XIV International Conference on Duchenne and Becker Muscular Dystrophy. The conference will be held February 13 - 14, 2016, in Rome, Italy, at the Church Palace.
CATB: 4.14 (+0.18)
Muscular Dystrophy Association to Collaborate with Catabasis Pharmaceuticals on Development of CAT-1004, a Potential Novel Oral Disease-Modifying Treatment for Duchenne Muscular Dystrophy
BusinessWire - Fri Feb 05, 7:00AM CST
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, and the Muscular Dystrophy Association (MDA), today announced a collaboration to support the Part B portion of the MoveDMD clinical trial of CAT-1004, a novel product candidate for the treatment of patients with Duchenne muscular dystrophy (DMD). Under the collaboration, MDA will provide funding for transportation to participants who need to travel to take part in the study. Part A of the MoveDMD trial has completed and Catabasis recently reported positive top-line results for safety, tolerability and pharmacokinetics. Part B of the trial is expected to initiate in the first half of 2016. The boys in Part A of the trial will be asked to participate in Part B and additional participants will also be enrolled. Catabasis is currently identifying additional patients who are interested in participating in Part B of the trial. Enrollment criteria for Part B are expected to be similar to those for Part A.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Announces Positive Top-Line Results from Part A of the MoveDMD(SM) Trial, a Phase 1 / 2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy
BusinessWire - Mon Jan 25, 7:00AM CST
--- Results Support Initiation of Part B of Trial, Expected in First Half of 2016 -
CATB: 4.14 (+0.18)
FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich's Ataxia
BusinessWire - Tue Jan 19, 7:00AM CST
The Friedreich's Ataxia Research Alliance (FARA) and Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announce that Catabasis Pharmaceuticals is the recipient of the Kyle Bryant Translational Research Award. Catabasis is a clinical-stage drug development company built on a pathway pharmacology technology platform. The two year award will be for the Evaluation of CAT-4001 in Frataxin-deficient mouse models and dorsal root ganglia neurons to enable its therapeutic development for Friedreich's ataxia. This work will be led by Dr. Andrew Nichols at Catabasis along with collaborators Dr. Mark Payne at Indiana University and Dr. Jordi Magrane at Weill Cornell College of Medicine who are expected to perform testing in the Friedreich's ataxia (FA) animal models.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Completes Enrollment for Part A of the MoveDMD(SM) Trial, a Phase 1/2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy
BusinessWire - Fri Dec 18, 7:00AM CST
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that enrollment is complete in Part A of the MoveDMD trial, a Phase 1/2 trial of CAT-1004 for the treatment of Duchenne muscular dystrophy (DMD). CAT-1004 is an oral small-molecule that the Company believes has the potential to be a disease-modifying therapy for DMD patients, regardless of the underlying dystrophin mutation. CAT-1004 is an inhibitor of NF-kB, a protein that is activated in DMD as well as multiple other skeletal muscle disorders. In animal models of DMD, CAT-1004 inhibited activated NF-kB, reduced muscle inflammation and degeneration and increased muscle regeneration. DMD is a rare disease that involves progressive muscle degeneration that eventually leads to death and for which there are no approved therapies in the United States.
CATB: 4.14 (+0.18)
Catabasis Names Deirdre Cunnane SVP, General Counsel
BusinessWire - Thu Dec 17, 7:00AM CST
Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that it has named Deirdre Cunnane, J.D., as senior vice president, general counsel. Ms. Cunnane brings to Catabasis over 25 years of legal counsel experience.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial of CAT-2054 for the Treatment of Hypercholesterolemia
BusinessWire - Wed Dec 09, 7:00AM CST
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that the first patient has been dosed in a Phase 2a trial of CAT-2054 for the treatment of hypercholesterolemia. CAT-2054 is an oral small molecule that modulates the SREBP pathway. SREBP is a master regulator of lipid metabolism that impacts LDL, triglycerides and glucose with the potential to impact liver fat and hepatocellular carcinoma.
CATB: 4.14 (+0.18)
Mallinckrodt DMD Drug Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:57AM CDT
Mallinckrodt (MNK) received Fast Track status in the U.S. for its IND application for Synacthen Depot for the treatment of Duchenne muscular dystrophy.
MNK: 74.10 (-1.31), CATB: 4.14 (+0.18), ANIP: 64.84 (+1.09), SRPT: 58.10 (+2.37)
Catabasis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights
BusinessWire - Thu Aug 11, 3:10PM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016 and corporate highlights.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals to Present at 2016 Wedbush PacGrow Healthcare Conference
BusinessWire - Tue Aug 09, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate and pipeline overview at the upcoming 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 1:20pm ET at the Le Parker Meridien Hotel in New York, NY.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals to Report Second Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, August 11
BusinessWire - Thu Jul 28, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2016 financial results after the NASDAQ Global Market close on Thursday, August 11, 2016. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 4:30pm ET to provide an update on corporate developments and to discuss second quarter financial results.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals to Present Edasalonexent (CAT-1004), an Oral Agent Targeting NF-kB: MoveDMD(SM) Trial in Duchenne Muscular Dystrophy (DMD) at the 2016 PPMD Annual Connect Conference
BusinessWire - Mon Jun 20, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that edasalonexent (CAT-1004) will be featured in an oral presentation and a poster presentation at the upcoming 2016 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference being held on Sunday, June 26 - Wednesday, June 29, 2016 at the Renaissance Orlando at Sea World Hotel in Orlando, FL.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on MoveDMD(SM): A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy
BusinessWire - Wed Jun 08, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Parent Project Muscular Dystrophy (PPMD) will host a webinar "MoveDMD: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy" this afternoon on Wednesday, June 8, 2016 at 1:00 pm ET.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Announces Top-Line Phase 2a Results for CAT-2054
BusinessWire - Tue Jun 07, 3:15PM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced top-line results from its Phase 2a clinical trial of CAT-2054 for the treatment of hypercholesterolemia. CAT-2054 is an oral product candidate that inhibits Sterol Regulatory Element-Binding Protein (SREBP), a master regulator of lipid metabolism in the body. The double-blind, placebo-controlled trial assessed the effects of four weeks of treatment with CAT-2054 in patients with hypercholesterolemia on a high-intensity statin. The trial did not meet the primary end point in hypercholesterolemia, reduction in LDL-cholesterol (LDL-C) from baseline. Additional pre-specified analyses included changes in liver function tests (LFTs) to assess potential activity in nonalcoholic steatohepatitis (NASH). In a pre-specified analysis of patients more likely to have NASH, a potentially favorable pattern in LFTs was seen despite relatively low baseline LFT values and short trial duration and needs further investigation. All four doses of CAT-2054 in the trial were generally well tolerated.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016; Data Support CAT-2054, a Phase 2 Asset, as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH)
BusinessWire - Sat May 21, 11:30AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced positive pre-clinical data supporting CAT-2054 as a potential treatment for nonalcoholic steatohepatitis (NASH). The data presented compared CAT-2003, an analog of CAT-2054, versus control in a murine metabolic model of NASH followed for up to 16 weeks. The CAT-2000 series are inhibitors of Sterol Regulatory Element-Binding Protein 1 (SREBP1) and SREBP2, master regulators of lipid metabolism. CAT-2003 demonstrated a significant decrease in gene expression markers of liver inflammation as well as a significant decrease in fibrosis and steatosis. Also seen were significantly reduced ballooning degeneration and significant reduction in the development of pre-neoplastic lesions in the liver, which are precursors to the development of hepatocellular carcinoma. CAT-2054 is an oral product candidate currently in a Phase 2a clinical trial in patients with hypercholesterolemia, which has completed enrollment; top-line results are expected around mid-year 2016.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals to Present Pre-Clinical Data Supporting CAT-2054 as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) at Digestive Disease Week 2016
BusinessWire - Mon May 16, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that pre-clinical data will be presented that supports CAT-2054 as a potential treatment for NASH at Digestive Disease Week 2016 held May 21 - 24, 2016, in San Diego, California at the San Diego Convention Center. The data that will be presented was generated using CAT-2003, an analog of CAT-2054, to demonstrate the potential of CAT-2054 in NASH. CAT-2054 is currently in a Phase 2a clinical trial in patients with hypercholesterolemia.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals to Present CAT-2054, a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) and Hypercholesterolemia, at the National Lipid Association 2016 Scientific Sessions
BusinessWire - Mon May 16, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present CAT-2054, a potential treatment for NASH and hypercholesterolemia, at the upcoming National Lipid Association 2016 Scientific Sessions held May 19 - 22, 2016, in New Orleans at the New Orleans Hyatt Regency Hotel.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Corporate Highlights
BusinessWire - Thu May 12, 3:05PM CDT
-- CAT-2054 as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) and Hypercholesterolemia: Promising Pre-Clinical Data in NASH; Phase 2a Trial in Hypercholesterolemia Fully Enrolled --
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals to Report First Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, May 12
BusinessWire - Thu Apr 28, 7:00AM CDT
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2016 financial results after the NASDAQ Global Market close on Thursday, May 12, 2016. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 4:30pm ET to provide an update on corporate developments and to discuss first quarter financial results.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Initiates Part B of the MoveDMD(SM) Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy
BusinessWire - Tue Apr 12, 7:00AM CDT
"Catabasis announced that dosing of the first patient has been initiated in Part B of the MoveDMD trial. They also announced positive biomarker results from Part A of the trial."
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the XIV International Conference on Duchenne and Becker Muscular Dystrophy
BusinessWire - Wed Feb 10, 7:00AM CST
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company focused on bringing transformative therapies to patients with rare diseases, today announced that Catabasis will present CAT-1004 for the treatment of Duchenne muscular dystrophy (DMD) and the MoveDMD(SM) trial design at the XIV International Conference on Duchenne and Becker Muscular Dystrophy. The conference will be held February 13 - 14, 2016, in Rome, Italy, at the Church Palace.
CATB: 4.14 (+0.18)
Muscular Dystrophy Association to Collaborate with Catabasis Pharmaceuticals on Development of CAT-1004, a Potential Novel Oral Disease-Modifying Treatment for Duchenne Muscular Dystrophy
BusinessWire - Fri Feb 05, 7:00AM CST
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, and the Muscular Dystrophy Association (MDA), today announced a collaboration to support the Part B portion of the MoveDMD clinical trial of CAT-1004, a novel product candidate for the treatment of patients with Duchenne muscular dystrophy (DMD). Under the collaboration, MDA will provide funding for transportation to participants who need to travel to take part in the study. Part A of the MoveDMD trial has completed and Catabasis recently reported positive top-line results for safety, tolerability and pharmacokinetics. Part B of the trial is expected to initiate in the first half of 2016. The boys in Part A of the trial will be asked to participate in Part B and additional participants will also be enrolled. Catabasis is currently identifying additional patients who are interested in participating in Part B of the trial. Enrollment criteria for Part B are expected to be similar to those for Part A.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Announces Positive Top-Line Results from Part A of the MoveDMD(SM) Trial, a Phase 1 / 2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy
BusinessWire - Mon Jan 25, 7:00AM CST
--- Results Support Initiation of Part B of Trial, Expected in First Half of 2016 -
CATB: 4.14 (+0.18)
FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich's Ataxia
BusinessWire - Tue Jan 19, 7:00AM CST
The Friedreich's Ataxia Research Alliance (FARA) and Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announce that Catabasis Pharmaceuticals is the recipient of the Kyle Bryant Translational Research Award. Catabasis is a clinical-stage drug development company built on a pathway pharmacology technology platform. The two year award will be for the Evaluation of CAT-4001 in Frataxin-deficient mouse models and dorsal root ganglia neurons to enable its therapeutic development for Friedreich's ataxia. This work will be led by Dr. Andrew Nichols at Catabasis along with collaborators Dr. Mark Payne at Indiana University and Dr. Jordi Magrane at Weill Cornell College of Medicine who are expected to perform testing in the Friedreich's ataxia (FA) animal models.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Completes Enrollment for Part A of the MoveDMD(SM) Trial, a Phase 1/2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy
BusinessWire - Fri Dec 18, 7:00AM CST
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that enrollment is complete in Part A of the MoveDMD trial, a Phase 1/2 trial of CAT-1004 for the treatment of Duchenne muscular dystrophy (DMD). CAT-1004 is an oral small-molecule that the Company believes has the potential to be a disease-modifying therapy for DMD patients, regardless of the underlying dystrophin mutation. CAT-1004 is an inhibitor of NF-kB, a protein that is activated in DMD as well as multiple other skeletal muscle disorders. In animal models of DMD, CAT-1004 inhibited activated NF-kB, reduced muscle inflammation and degeneration and increased muscle regeneration. DMD is a rare disease that involves progressive muscle degeneration that eventually leads to death and for which there are no approved therapies in the United States.
CATB: 4.14 (+0.18)
Catabasis Names Deirdre Cunnane SVP, General Counsel
BusinessWire - Thu Dec 17, 7:00AM CST
Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that it has named Deirdre Cunnane, J.D., as senior vice president, general counsel. Ms. Cunnane brings to Catabasis over 25 years of legal counsel experience.
CATB: 4.14 (+0.18)
Catabasis Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial of CAT-2054 for the Treatment of Hypercholesterolemia
BusinessWire - Wed Dec 09, 7:00AM CST
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that the first patient has been dosed in a Phase 2a trial of CAT-2054 for the treatment of hypercholesterolemia. CAT-2054 is an oral small molecule that modulates the SREBP pathway. SREBP is a master regulator of lipid metabolism that impacts LDL, triglycerides and glucose with the potential to impact liver fat and hepatocellular carcinoma.
CATB: 4.14 (+0.18)
(0)
(0)Scroll down for more posts ▼